Use of a new acellular dermal matrix for treatment of nonhealing wounds in the lower extremities of patients with diabetes.
Acellular dermal matrices (ADMs) have successfully been used in the treatment of nonhealing wounds in patients with diabetes. A new decellularized biological scaffold derived from human skin, D-ADM, (DermACELL, LifeNet Health, Virginia Beach, VA), has shown increased cell infiltration, host tissue integration, and vascularization in comparison to other ADMs. This clinical investigation evaluated the wound closing properties of D-ADM on 18 full-thickness lower extremity wounds in 15 patients with diabetes over a period of 12 weeks. A complete wound closure (100% epithelialization) rate of 58% (7/12) and an average duration of 10 weeks was demonstrated. Wound healing, defined as ≥ 95% wound closure, was established in 83% of the wounds (10/12) by the end of the study treatment. These results compare favorably with other methods of advanced wound care treatment options that utilize skin substitutes to accelerate the healing of difficult-to-treat or chronic wounds.